VA
CRSP icon

Vident Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Vident Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,104
Closed -$762K – 1448
2024
Q2 		$762K Buy
14,104
+61
+0.4% +$3.53K 0.02% 698
2024
Q1 		$957K Buy
14,043
+3,561
+34% +$255K 0.02% 586
2023
Q4 		$656K Buy
10,482
+357
+4% +$19.7K 0.02% 684
2023
Q3 		$460K Buy
+10,125
New +$523K 0.01% 730

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vident Advisory's CRSP Position: Q3 2024 in Review

Vident Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 14,104 shares — an estimated $762K sold.

Vident Advisory first reported a position in CRSP in Q3 2023 and held it in 4 quarters. The position peaked at $957K in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Vident Advisory reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 14,104 CRISPR Therapeutics shares in Q3 2024, an estimated $762K.
  • Vident Advisory first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's CRISPR Therapeutics position peaked at $957K in Q1 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.